(BRKR) Bruker - Ratings and Ratios
Spectrometers, Microscopes, Magnets, Analyzers, Diagnostics
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.50% |
| Yield on Cost 5y | 0.35% |
| Yield CAGR 5y | 5.74% |
| Payout Consistency | 96.4% |
| Payout Ratio | 11.6% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 49.6% |
| Value at Risk 5%th | 77.6% |
| Relative Tail Risk | -4.94% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.12 |
| Alpha | -33.40 |
| CAGR/Max DD | -0.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.404 |
| Beta | 1.194 |
| Beta Downside | 0.942 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.72% |
| Mean DD | 32.09% |
| Median DD | 31.30% |
Description: BRKR Bruker January 08, 2026
Bruker Corporation (NASDAQ:BRKR) designs, manufactures and sells a broad portfolio of scientific and analytical instruments-including magnetic-resonance spectrometers, mass-spectrometry platforms, X-ray and electron-microscopy tools, and nanometer-scale metrology equipment-through four operating segments (BSI BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Superconducting Technologies). The firm serves life-science, pharmaceutical, materials-science and industrial customers worldwide, offering both hardware and integrated software/automation services.
Key quantitative points: (1) FY 2024 revenue rose ~7% YoY to roughly $1.9 bn, driven by a 12% surge in the BSI BioSpin and Nano divisions as pharma R&D spend expands; (2) R&D intensity remains high at ~13% of sales, supporting a pipeline of next-gen MALDI-TOF and cryo-EM solutions; (3) The global analytical instrumentation market is projected to grow at a 6-8% CAGR through 2028, underpinned by increasing demand for high-throughput drug discovery and advanced materials characterization. These macro trends and Bruker’s diversified product mix suggest a resilient revenue base, though cyclicality in capital-equipment budgets could add volatility.
For a deeper, data-driven look at BRKR’s valuation and peer landscape, you may find ValueRay’s analytical dashboard useful.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -20.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -2.73 > 1.0 |
| NWC/Revenue: 31.48% < 20% (prev 26.82%; Δ 4.66% < -1%) |
| CFO/TA 0.01 > 3% & CFO 94.3m > Net Income -20.9m |
| Net Debt (1.75b) to EBITDA (288.6m): 6.08 < 3 |
| Current Ratio: 1.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (151.8m) vs 12m ago -0.13% < -2% |
| Gross Margin: 47.36% > 18% (prev 0.49%; Δ 4687 % > 0.5%) |
| Asset Turnover: 54.81% > 50% (prev 53.02%; Δ 1.79% > 0%) |
| Interest Coverage Ratio: 1.14 > 6 (EBITDA TTM 288.6m / Interest Expense TTM 64.4m) |
Altman Z'' 2.98
| A: 0.17 (Total Current Assets 2.35b - Total Current Liabilities 1.27b) / Total Assets 6.43b |
| B: 0.37 (Retained Earnings 2.35b / Total Assets 6.43b) |
| C: 0.01 (EBIT TTM 73.5m / Avg Total Assets 6.27b) |
| D: 0.58 (Book Value of Equity 2.27b / Total Liabilities 3.94b) |
| Altman-Z'' Score: 2.98 = A |
Beneish M -3.04
| DSRI: 0.89 (Receivables 673.4m/712.9m, Revenue 3.44b/3.24b) |
| GMI: 1.03 (GM 47.36% / 48.95%) |
| AQI: 1.03 (AQ_t 0.52 / AQ_t-1 0.50) |
| SGI: 1.06 (Revenue 3.44b / 3.24b) |
| TATA: -0.02 (NI -20.9m - CFO 94.3m) / TA 6.43b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
ValueRay F-Score (Strict, 0-100) 41.97
| 1. Piotroski: 3.0pt |
| 2. FCF Yield: -0.11% |
| 3. FCF Margin: -0.31% |
| 4. Debt/Equity: 0.84 |
| 5. Debt/Ebitda: 6.08 |
| 6. ROIC - WACC: -7.25% |
| 7. RoE: -1.07% |
| 8. Revenue Trend: 83.24% |
| 9. EPS Trend: -50.49% |
What is the price of BRKR shares?
Over the past week, the price has changed by -2.81%, over one month by +0.90%, over three months by +25.49% and over the past year by -13.05%.
Is BRKR a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BRKR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 54.1 | 11.6% |
| Analysts Target Price | 54.1 | 11.6% |
| ValueRay Target Price | 50.7 | 4.6% |
BRKR Fundamental Data Overview January 22, 2026
P/S = 2.2021
P/B = 3.1139
P/EG = 3.64
Revenue TTM = 3.44b USD
EBIT TTM = 73.5m USD
EBITDA TTM = 288.6m USD
Long Term Debt = 1.98b USD (from longTermDebt, last quarter)
Short Term Debt = 24.3m USD (from shortTermDebt, last quarter)
Debt = 2.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.75b USD (from netDebt column, last quarter)
Enterprise Value = 9.33b USD (7.57b + Debt 2.05b - CCE 295.0m)
Interest Coverage Ratio = 1.14 (Ebit TTM 73.5m / Interest Expense TTM 64.4m)
EV/FCF = -879.9x (Enterprise Value 9.33b / FCF TTM -10.6m)
FCF Yield = -0.11% (FCF TTM -10.6m / Enterprise Value 9.33b)
FCF Margin = -0.31% (FCF TTM -10.6m / Revenue TTM 3.44b)
Net Margin = -0.61% (Net Income TTM -20.9m / Revenue TTM 3.44b)
Gross Margin = 47.36% ((Revenue TTM 3.44b - Cost of Revenue TTM 1.81b) / Revenue TTM)
Gross Margin QoQ = 44.88% (prev 44.88%)
Tobins Q-Ratio = 1.45 (Enterprise Value 9.33b / Total Assets 6.43b)
Interest Expense / Debt = 0.98% (Interest Expense 20.0m / Debt 2.05b)
Taxrate = 44.54% (91.4m / 205.2m)
NOPAT = 40.8m (EBIT 73.5m * (1 - 44.54%))
Current Ratio = 1.85 (Total Current Assets 2.35b / Total Current Liabilities 1.27b)
Debt / Equity = 0.84 (Debt 2.05b / totalStockholderEquity, last quarter 2.43b)
Debt / EBITDA = 6.08 (Net Debt 1.75b / EBITDA 288.6m)
Debt / FCF = -165.5 (out of range, set to none) (Net Debt 1.75b / FCF TTM -10.6m)
Total Stockholder Equity = 1.96b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.33% (Net Income -20.9m / Total Assets 6.43b)
RoE = -1.07% (Net Income TTM -20.9m / Total Stockholder Equity 1.96b)
RoCE = 1.86% (EBIT 73.5m / Capital Employed (Equity 1.96b + L.T.Debt 1.98b))
RoIC = 0.99% (NOPAT 40.8m / Invested Capital 4.12b)
WACC = 8.24% (E(7.57b)/V(9.62b) * Re(10.32%) + D(2.05b)/V(9.62b) * Rd(0.98%) * (1-Tc(0.45)))
Discount Rate = 10.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.97%
Fair Price DCF = unknown (Cash Flow -10.6m)
EPS Correlation: -50.49 | EPS CAGR: -46.35% | SUE: -4.0 | # QB: 0
Revenue Correlation: 83.24 | Revenue CAGR: 6.33% | SUE: 0.69 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.41 | Chg30d=-0.011 | Revisions Net=-1 | Analysts=11
EPS next Year (2026-12-31): EPS=2.14 | Chg30d=-0.013 | Revisions Net=-1 | Growth EPS=+13.8% | Growth Revenue=+1.5%
Additional Sources for BRKR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle